Metoclopramide increased cell proliferation in HepG2 cell line and sorafenib attenuated the effect

Basit Öğe Kaydı
dc.authorid0000-0002-3060-1507en_US
dc.authorid0000-0002-4605-1167en_US
dc.authorid0000-0002-6733-2136en_US
dc.authorid0000-0002-0021-8400en_US
dc.authorid0000-0002-4474-7371en_US
dc.date.accessioned2024-07-12T21:01:41Z
dc.date.available2024-07-12T21:01:41Z
dc.date.issued2020en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractİnönü Üniversitesi Tıp Fakültesi Abstract Aim: Metoclopramide is an antiemetic drug used for treating postoperative or chemotherapy-induced emesis. Sorafenib is a kinase inhibitor drug and is approved for the treatment of advanced primary liver cancer, renal cell carcinoma, thyroid cancer, and acute myeloid leukemia. Hepatocellular cancer is a common cause of cancer-related death and its treatment may require coadministration of an antiemetic medication. The study aims to investigate the effect of metoclopramide on hepatocellular cancer cell proliferation alone or in combination with sorafenib. Material and Methods: Metoclopramide doses of 0.17 µM to 25 µM alone or in combination with sorafenib were administered to human hepatocellular cancer cell line, HepG2. Cell viability and proliferation test was used to determine the possible effects on proliferation. Hematoxylin and Eosin staining was performed to visualize the morphological effects of the treatments. Results: Metoclopramide doses of 0.58 µM, 25µM increased cell proliferation when compared to the control group. Metoclopramide combination groups with 9.9 µM sorafenib were compared with control and sorafenib groups. Each combination group was comparable with the control group. Metoclopramide increased proliferation in certain doses. Safety concerns about its use in hepatocellular cancer should be confirmed in clinical trials Each combination group was comparable with the control group. Conclusion: Metoclopramide increased proliferation in certain doses. Sorafenib inhibited the effect. Safety concerns about its use in hepatocellular cancer should be addressed in clinical trialsen_US
dc.identifier.citationGüneş Özünal, Z., Dönmez Çakıl, Y., Tekin, S., Sağlam, E. ve Gülhan Aktaş, R. (2020). Metoclopramide increased cell proliferation in HepG2 cell line and sorafenib attenuated the effect. Annals of Medical Research, İnönü Üniversitesi Tıp Fakültesi. 27(4), s. 1188-1192.en_US
dc.identifier.doi10.5455/annalsmedres.2020.02.179
dc.identifier.endpage1192en_US
dc.identifier.issn2636-7688
dc.identifier.issn1300-1744
dc.identifier.issue4en_US
dc.identifier.startpage1188en_US
dc.identifier.trdizinid362380en_US
dc.identifier.urihttps://www.annalsmedres.org/articles-and-issues/current-issues/item/1516-metoclopramide-increased-cell-proliferation-in-hepg2-cell-line-and-sorafenib-attenuated-the-effect-p-1188-92.html
dc.identifier.urihttps://doi.prg/10.5455/annalsmedres.2020.02.179
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3526
dc.identifier.volume27en_US
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorGüneş Özünal, Zeynep
dc.institutionauthorDönmez Çakıl, Yaprak
dc.institutionauthorTekin, Sena
dc.institutionauthorSağlam, Esra
dc.institutionauthorAktaş, Ranan
dc.language.isoenen_US
dc.publisherİnönü Üniversitesi Tıp Fakültesien_US
dc.relation.ispartofAnnals of Medical Researchen_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsCC0 1.0 Universal*
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.snmzKY00261
dc.subjectHepatocellular canceren_US
dc.subjectmetoclopramideen_US
dc.subjectpharmacologyen_US
dc.subjectsorafeniben_US
dc.titleMetoclopramide increased cell proliferation in HepG2 cell line and sorafenib attenuated the effecten_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu